WOONSOCKET, R.I., June 04, 2024 (GLOBE NEWSWIRE) -- Surplus Solutions, a leader in Equipment Lifecycle Management (ELM) services, announces the…
MOJO to be offered as an Oral Dissolvable Tablet (ODT) marketed to younger male demographic as an alternative to PRIME…
Data from Phase 2 and 2/3 trials demonstrate continued efficacy and safety of vebreltinib for treating different tumor types carrying…
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies…
Scientific Advisory Board to play pivotal role in guiding and accelerating bezisterim long COVID Phase 2b trial supported by an…
PetVivo Holdings, Inc. April Boyce MINNEAPOLIS, MN, US, June 04, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTC Pink: PETV…
- In Cohort 5 of PROPEL 2 (0.25 mg/kg/day), oral treatment with infigratinib resulted in a statistically significant and sustained…
-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO…
Nanotechnology performance from testing will provide insights to continue to advance towards commercial productionOakville, Ontario--(Newsfile Corp. - June 4, 2024)…
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 4, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that on June 3,…